Holen Sie sich die Stockscreener-App
48.97
1.26%
0.56
Handel nachbörslich:
48.98
0.010
+0.02%
Schlusskurs vom Vortag:
$48.41
Offen:
$48.515
24-Stunden-Volumen:
4.11M
Relative Volume:
0.66
Marktkapitalisierung:
$8.80B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$-302.91M
KGV:
-28.50
EPS:
-1.7182
Netto-Cashflow:
$-219.93M
1W Leistung:
-16.45%
1M Leistung:
-3.58%
6M Leistung:
-24.95%
1J Leistung:
-15.50%
1-Tages-Spanne:
$47.74
$50.01
1-Wochen-Bereich:
$47.43
$59.94
52-Wochen-Spanne:
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Firmenname
Tempus Ai Inc
Sektor
Branche
Telefon
800-976-5448
Adresse
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
48.98 | 8.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
189.22 | 32.07B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
72.56 | 13.84B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
97.72 | 8.27B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
84.38 | 6.79B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Underperform |
| 2026-04-13 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | Mizuho | Outperform |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-21 | Eingeleitet | BTIG Research | Buy |
| 2025-02-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Fortgesetzt | TD Cowen | Buy |
| 2024-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-09 | Eingeleitet | Guggenheim | Buy |
| 2024-11-11 | Herabstufung | Stifel | Buy → Hold |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-08-12 | Eingeleitet | Piper Sandler | Neutral |
| 2024-07-09 | Eingeleitet | BofA Securities | Buy |
| 2024-07-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-07-09 | Eingeleitet | Longbow | Buy |
| 2024-07-09 | Eingeleitet | Loop Capital | Buy |
| 2024-07-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-07-09 | Eingeleitet | Needham | Buy |
| 2024-07-09 | Eingeleitet | Stifel | Buy |
| 2024-07-09 | Eingeleitet | TD Cowen | Buy |
| 2024-07-09 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Tempus Ai Inc Aktie (TEM) Neueste Nachrichten
Artificial Intelligence Stocks To Add to Your WatchlistJuly 21st - MarketBeat
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI Stock Short Interest Falls to 33.94% - Quiver Quantitative
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Yahoo Finance
Tempus AI, Inc. $TEM Stake Boosted by Amova Asset Management Americas Inc. - MarketBeat
Tempus AI (TEM) to Acquire Personalis in Strategic Move - GuruFocus
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Personalis, Inc. (PSNL) Tempus AI, Inc.M&A CallSlideshow (NASDAQ:PSNL) 2026-07-20 - Seeking Alpha
Jefferies reiterates Tempus AI stock rating on acquisition concerns By Investing.com - Investing.com South Africa
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink -- Barrons.com - Moomoo
Latham, Cooley Steer $1.5B Tempus Cancer Testing Deal - Law360
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL) - Stock Titan
Personalis (NASDAQ: PSNL) agrees to stock-for-stock merger with Tempus AI - Stock Titan
Tempus AI Announces Merger Agreement to Acquire Personalis - TipRanks
Jefferies reiterates Tempus AI stock rating on acquisition concerns - Investing.com
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Dea - GuruFocus
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis - MedCity News
Needham cuts Personalis stock rating on Tempus AI acquisition By Investing.com - Investing.com South Africa
Tempus finds time right for $1.5B Personalis MRD grab - BioWorld News
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal - TradingView
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis - Latham & Watkins LLP
Needham cuts Personalis stock rating on Tempus AI acquisition - Investing.com UK
Tempus to acquire cancer test maker Personalis for $1.5B - BioPharma Dive
Tempus AI stock maintains Buy rating after Personalis acquisition By Investing.com - Investing.com Australia
Tempus AI to acquire Personalis for $1.5B - The Business Journals
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal - TradingView
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink - Barron's
Tempus to buy cancer test-maker Personalis for $1.5B - MedTech Dive
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Benzinga
Market movers: AMC Entertainment, Hut 8, Domino’s Pizza, Tempus AI… - Proactive Investors
Why is Tempus AI stock sliding today? By Investing.com - Investing.com Nigeria
Tempus AI Plunges as Investors Question $1.5 Billion Cash Buyout of Personalis - finance.biggo.com
Needham reiterates Tempus AI stock rating after Personalis deal By Investing.com - Investing.com South Africa
AI Hardware Deals Trigger A Rough Day For Small Caps - Finimize
Tempus AI stock maintains Buy rating after Personalis acquisition - Investing.com
TEM Reiterated by Needham -- Price Target Maintained at $75 - GuruFocus
Needham reiterates Tempus AI stock rating after Personalis deal - Investing.com
Tempus AI (NASDAQ:TEM) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Tempus AI (NASDAQ:TEM) Shares Drop Close to $46 Merger Price - TechStock²
Tempus AI, Inc. entered into a definitive agreement to acquire remaining 87.85% stake in Personalis, Inc. for $1.6 billion. - marketscreener.com
Tempus AI to buy cancer-tech firm Personalis for $1.7B - Modern Healthcare
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition - Benzinga
Tempus AI to buy Personalis to strengthen its position in cancer screening - marketscreener.com
Tempus AI (NASDAQ:TEM) Shares Gap DownTime to Sell? - MarketBeat
Promising Artificial Intelligence Stocks To ResearchJuly 20th - MarketBeat
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition - MarketBeat
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus - GlobeNewswire Inc.
Tempus to acquire Personalis for $1.5 billion By Investing.com - Investing.com Nigeria
Finanzdaten der Tempus Ai Inc-Aktie (TEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
7.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):